Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05567159 · ClinicalTrials.gov registry record · Phase 1
A Study of Donanemab (LY3002813) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT05567159 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 42 participants.
The verdict
NCT05567159, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess how fast donanemab (LY3002813) gets into the blood stream and how long it takes the body to remove it when administered as single dose in healthy participants. The study will also evaluate the safety and tolerability of donanemab. The study will last up to approximately 22 weeks.
Interventions
- DRUG Donanemab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-10-04 |
| Est. Completion | 2023-07-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05567159
The ClinicalTrials.gov registry entry for NCT05567159 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Donanemab is the first listed.
NCT05567159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05567159 about?
NCT05567159 is a clinical study titled "A Study of Donanemab (LY3002813) in Healthy Participants". The main purpose of this study is to assess how fast donanemab (LY3002813) gets into the blood stream and how long it takes the body to remove it when administered as single dose in healthy participants. The study will also evaluate the safety and tolerability of donanemab. The study will last up to...
What is the current status of trial NCT05567159?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-10-04. Estimated completion is 2023-07-14.
What interventions are being tested in trial NCT05567159?
The interventions under investigation include: Donanemab (DRUG).
Who is sponsoring clinical trial NCT05567159?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.